Longevity Diagnostics Research



A small pilot study of Qualia Life—originally branded as Eternus—was conducted on 9 individuals in November-December 2019 as part of a larger research project by Longevity Diagnostics Research. The primary objective was to understand whether NAD+, and the levels of other molecules in the NAD metabolome, would change from baseline after 5-days and 4-weeks of supplementing with Qualia Life.

Venipuncture—standard blood draw with whole blood and plasma samples—was taken at three time points: (1) Initial visit to obtain samples for baseline; (2) After 5 days of taking Qualia Life; and (3) After 4 weeks of taking Qualia Life.

After completing the initial blood draw, each participant was given a four week supply of Qualia Life and instructed to take eight capsules daily, between about 7-9 am with a glass of water for five days, followed by two days where no capsules would be taken. This five-days on, two-days off schedule continued for four weeks.

The Results

The results suggest that supplementation with Qualia Life may produce meaningful changes in molecules within the NAD metabolome in whole blood and plasma after both 5 days and 4 weeks.

Some Important Changes in Whole Blood After 4 Weeks Were:
100% increase in NAD+ (p = 0.0555; effect size = 0.7)
77% increase in NMN (p = 0.0003; effect size = 2.0)
103% increase in NADH (p = 0.0152; effect size = 1.0)

Ten individuals—7 male and 3 females with ages ranging from 30 to 83 years old—participated. All ten completed testing after 5 days of taking Qualia Life. One individual, a male 30 years of age, was unable to attend the final venipuncture visit because of an emergent family issue, resulting in 4-week data being available for 9 out of the 10 original participants.

Summary Table
(percent change from baseline measurement)
  Qualia Life
(full dose)
5 days
Qualia Life
(full dose)
4 weeks
Qualia Life
(full dose)
5 days
Qualia Life
(full dose)
4 weeks
NAD+ 85% 100%* 7%** 69%*
NMN 66%*** 77%*** 14%* 40%**
NR 6% 19% 45%** 49%**
NADH 85%* 103%** 3% 54%*
* p<0.1; ** p<0.05; *** p<0.01
Abbreviations: NAD+ = Nicotinamide Adenine Dinucleotide; NMN = Nicotinamide Mononucleotide; NR = Nicotinamide Riboside; NADH = Reduced form of Nicotinamide Adenine Dinucleotide.


Measurable increases in NAD+ were detected in whole blood after 5 days of Qualia Life supplementation. NAD+ levels increased further after 4 weeks. The 100% relative increase in whole blood NAD+ was greater than what’s been reported for a 300 mg dose of nicotinamide riboside (NR) [1,2].

Plasma NAD+ increased by 69% after 4 weeks of Qualia Life supplementation. To our knowledge this is the first report of plasma NAD+ levels increasing significantly following any type of oral supplementation.

After 4 weeks of supplementation, whole blood NMN levels increased by 77% and plasma levels increased by 40%. This occurred despite the absence of any NMN or NR in Qualia Life. As a comparison, supplementation with 1000 mg of NR—about 3.3 times the recommended daily dose—daily for 21 days has only increased NMN in whole blood by about 50% [3].

Despite not containing any NR, plasma NR increased by 45% and 49% from baseline after 5 days and 4 weeks of Qualis Life supplementation. To our knowledge, this is the first report of a significant increase in plasma NR levels in any study that has supplied NAD+ precursors orally.

Qualia Life increased whole blood NR by 19%. While this result was not statistically significant, the modest increase may be noteworthy, because an increase in whole blood NR was not detected compared to baseline in a study that supplemented a 1000 mg dose of NR for 21-days [3].

NADH is the reduced form of NAD+ in the redox pair​ and is used to carry electrons from the citric acid cycle to be used in oxidative phosphorylation (OXPHOS) for production of ATP. NADH increased in whole blood by 103% and plasma by 54% after 4 weeks of Qualia Life. The increases in whole blood and plasma NADH were similar to those found with NAD+. Studies of supplementation with NR have not reported NADH results, so comparisons are not possible.

Several factors should be kept in mind when interpreting the results. The study contained a small number of participants and was not placebo-controlled. It was part of a larger study that was being conducted for the purpose of obtaining information on different collection and preparation methods for measuring NAD+ and related molecules. It should be noted that the absolute value of the baseline concentration of NAD+ in whole blood was lower than previously reported (using different methodology) [3,4]. The baseline concentrations of NAD+ in plasma were similar to what’s been previously reported [5]. As part of the research project, Longevity Diagnostics Research is evaluating the comparative methodologies and their method to see if they can improve on absolute vs relative quantification of NAD+. Baseline concentrations of NMN and NR in whole blood and plasma were similar to what’s been previously reported [3,5]. While Neurohacker Collective is encouraged by the results of this preliminary pilot study, further controlled, larger studies will be required to verify the findings.

Note: The mean changes for the group of participants are reported; however, some individuals experienced smaller, and others larger changes, so the results are not intended to represent or guarantee that anyone will achieve the same or similar results.


This pilot study was conducted under IRB (OHRP#: 0001099) granted to Longevity Bridge. The IRB was approved with the purpose of obtaining information on the effectiveness of different collection and preparation methods for measuring NAD biomarkers. Neurohacker Collective decided to participate in the research project to support Longevity Bridge in their efforts to advance the science of NAD metabolome testing. After completion of the intervention stage of the study, and prior to the lab analyzing samples and reporting results, Longevity Bridge was purchased and renamed Longevity Diagnostics Research. For more information visit


  1. Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease. 2017;3: 17. doi:10.1038/s41514-017-0016-9
  2. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. 2019. doi:10.1038/s41598-019-46120-z
  3. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28: 1717–1728.e6. doi:10.1016/j.celrep.2019.07.043
  4. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12: e0186459. doi:10.1371/journal.pone.0186459
  5. Clement J, Wong M, Poljak A, Sachdev P, Braidy N. The Plasma NAD+ Metabolome Is Dysregulated in “Normal” Aging. Rejuvenation Res. 2018. doi:10.1089/rej.2018.2077